Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Amicus Therapeutics, Inc is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 584 staff and has a trailing 12-month revenue of around USD$226.9 million.
|Latest market close||USD$22.64|
|52-week range||USD$6.25 - USD$17.67|
|50-day moving average||USD$14.3515|
|200-day moving average||USD$13.5894|
|Wall St. target price||USD$19.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.13|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-0.53%|
|1 month (2020-11-06)||10.60%|
|3 months (2020-09-04)||66.35%|
|6 months (2020-06-05)||75.64%|
|1 year (2019-12-05)||125.95%|
|2 years (2018-12-04)||128.23%|
|3 years (2017-12-05)||80.98%|
|5 years (2015-12-04)||115.00%|
|Revenue TTM||USD$226.9 million|
|Gross profit TTM||USD$160.3 million|
|Return on assets TTM||-21.04%|
|Return on equity TTM||-60.97%|
|Market capitalisation||USD$4.4 billion|
TTM: trailing 12 months
There are currently 29.8 million Amicus Therapeutics shares held short by investors – that's known as Amicus Therapeutics's "short interest". This figure is 1.3% down from 30.2 million last month.
There are a few different ways that this level of interest in shorting Amicus Therapeutics shares can be evaluated.
Amicus Therapeutics's "short interest ratio" (SIR) is the quantity of Amicus Therapeutics shares currently shorted divided by the average quantity of Amicus Therapeutics shares traded daily (recently around 2.0 million). Amicus Therapeutics's SIR currently stands at 15.23. In other words for every 100,000 Amicus Therapeutics shares traded daily on the market, roughly 15230 shares are currently held short.
However Amicus Therapeutics's short interest can also be evaluated against the total number of Amicus Therapeutics shares, or, against the total number of tradable Amicus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amicus Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Amicus Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.116% of the tradable shares (for every 100,000 tradable Amicus Therapeutics shares, roughly 116 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Amicus Therapeutics.
Find out more about how you can short Amicus Therapeutics stock.
We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $6.25 up to $17.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 1.1704. This would suggest that Amicus Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.